EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	465.49B
Revenue (ttm)	96.04B
Net Income (ttm)	24.87B
Shares Out	36.62M
EPS (ttm)	n/a
PE Ratio	18.72
Forward PE	10.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	275,173
Average Volume	129,852
Open	12,740
Previous Close	12,690
Day's Range	12,660 - 13,240
52-Week Range	9,620 - 18,800
Beta	0.52
RSI	46.64
Earnings Date	May 9, 2025

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for pidemics in South Korea. It offers Euvichol, Euvichol Plus, and Euvichol-S, an oral cholera vaccine developed to prevent cholera; and EuCorVac-19, a subunit vaccine.The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits; and rCRM197, a diphtheria toxoid vaccine. In addition, it offers CMO services comprising of drug product production, cell bank production, drug product production, and drug substance production. Further, t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650

Financial Performance

In 2023, EuBiologics's revenue was 69.37 billion, an increase of 25.06% compared to the previous year's 55.47 billion. Losses were -13.88 billion, 1163.0% more than in 2022.